Compare Campbell Soup Co. (CPB) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Johnson & Johnson — how do they compare? Campbell Soup Co. trades at $19.1 (market cap $5.78B), while Johnson & Johnson trades at $260.76 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 106.9× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Johnson & Johnson for 129 Days on average.
| CPB | JNJ | |
|---|---|---|
Market Cap | $5.78B | $618.09B |
Volume | 11,705,427 | 6,050,983 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $278.43 |
52-Week Low | $18.90 | $186.00 |
Typical Hold Time | 98 Days | 129 Days |
Enterprise Value | $12.83B | $646.37B |
Dividend Yield | 5.16% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 earnings, beating expectations but showing margin pressure. Recent dividend cut of 36% and workforce reduction signal turnaround efforts amid declining profitability. Valuation appears reasonable with P/E of 14.79 and P/S of 0.6, but revenue growth remains challenged.
The outlook remains cautious with analyst consensus leaning heavily toward Hold (58.62%). While cost-saving initiatives and balance sheet improvements provide some support, persistent margin compression and competitive pressures create headwinds. The stock trades near the lower end of analyst targets ($18-22), offering limited upside potential amid ongoing operational challenges.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
